CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Supplement +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01915173
NCT01915173N/ACompleted
CompareCT.gov

Response to Supplement and Placebo in GERD

Beth Israel Deaconess Medical Center·interventional·Posted Aug 2, 2013·Updated Mar 29, 2017

In Brief

A clinical study evaluating Supplement, Placebo, and 2 other interventions for Gastroesophageal Reflux Disease (GERD) and 2 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux disease (GERD). This study is designed as a pilot trial to assess safety and feasibility and to provide preliminary estimates of effect sizes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2, 2013
Enrollment StartJun 1, 2013
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.9 years ago

Interventions

Supplementdrug

Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C

Placebodrug

Lactose tablets

Expanded Interviewbehavioral

Standard Interviewbehavioral